Literature DB >> 11745422

Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs.

R Yang1, D Xu, A Zhang, A Gruber.   

Abstract

Dendritic cells (DCs) can acquire antigen(s) from apoptotic tumor cells, resulting in an immunogen that can induce class I-restricted cytotoxic T lymphocytes (CTLs) and protective tumor rejection. Here, we investigated whether DCs derived from ascitic monocytes of patients with ovarian carcinoma could kill autologous ovarian tumor cells and if as a result they would acquire antigen(s) enabling them to induce a tumor-specific immunity. We found that the immature DCs could exert a significant cytotoxicity towards autologous and allogeneic ovarian tumor cells. This cytotoxicity was independent of Ca(2+) and could be inhibited by anti-Fas IgG1 monoclonal antibody, indicating the involvement of the Fas/Fas ligand (FasL) pathway in the cytotoxic mechanism. Further supporting this conclusion, the ascitic monocyte-derived DCs expressed high levels of FasL mRNA and intracellular FasL and significant levels of Fas were also revealed on the surface of ovarian tumor cells. Coculture of DCs induced apoptosis in ovarian carcinoma cells, as well as uptake of apoptotic tumor cells into the cytoplasma of the DCs, as visualized by immunofluoresence. Autologous DCs cocultured with apoptotic ovarian tumor cells were able to specifically stimulate tumor-specific CTLs, whereas DCs cocultured with necrotic ovarian cells were unable to do so. Collectively, these results demonstrate that immature DCs can kill autologous ovarian carcinoma cells via the Ca(2+)-independent Fas/FasL pathway and that this may have important consequences for their ability to stimulate tumor-specific CTLs. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745422     DOI: 10.1002/ijc.1484

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism.

Authors:  Collin J LaCasse; Nona Janikashvili; Claire B Larmonier; Darya Alizadeh; Neale Hanke; Jessica Kartchner; Elaine Situ; Sara Centuori; Michael Har-Noy; Bernard Bonnotte; Emmanuel Katsanis; Nicolas Larmonier
Journal:  J Immunol       Date:  2011-11-09       Impact factor: 5.422

2.  Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3LL tumor cells to mediate MDSC chemoattraction via Fas signaling.

Authors:  Fei Yang; Yinxiang Wei; Zhijian Cai; Lei Yu; Lingling Jiang; Chengyan Zhang; Huanmiao Yan; Qingqing Wang; Xuetao Cao; Tingbo Liang; Jianli Wang
Journal:  Cell Mol Immunol       Date:  2014-04-28       Impact factor: 11.530

3.  Cytotoxic dendritic cells generated from cancer patients.

Authors:  Daniela Lakomy; Nona Janikashvili; Jennifer Fraszczak; Malika Trad; Sylvain Audia; Maxime Samson; Marion Ciudad; Julien Vinit; Catherine Vergely; Denis Caillot; Pascal Foucher; Laurent Lagrost; Salem Chouaib; Emmanuel Katsanis; Nicolas Larmonier; Bernard Bonnotte
Journal:  J Immunol       Date:  2011-07-29       Impact factor: 5.422

Review 4.  Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.

Authors:  Neale Hanke; Darya Alizadeh; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

5.  Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity.

Authors:  Terutsugu Koya; Ryu Yanagisawa; Yumiko Higuchi; Kenji Sano; Shigetaka Shimodaira
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

Review 6.  Tumoricidal activity of human dendritic cells.

Authors:  Jurjen Tel; Sébastien Anguille; Claire E J Waterborg; Evelien L Smits; Carl G Figdor; I Jolanda M de Vries
Journal:  Trends Immunol       Date:  2013-11-18       Impact factor: 16.687

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.